Skip header and navigation

Refine By

255 records – page 2 of 26.

American Academy of Pediatrics. Preventive health care for young children: Findings from a 10-country study and directions for United States policy.

https://arctichealth.org/en/permalink/ahliterature36720
Source
Pediatrics. 1992 May;89(5 Pt 2):981-98
Publication Type
Article
Date
May-1992
Author
B C Williams
C A Miller
Author Affiliation
Department of Maternal and Child Health, School of Public Health, University of North Carolina, Chapel Hill 27599-7400.
Source
Pediatrics. 1992 May;89(5 Pt 2):981-98
Date
May-1992
Language
English
Publication Type
Article
Keywords
Adolescent
Child
Child Advocacy
Child Health Services - economics - organization & administration - standards
Child Welfare
Child, Preschool
Comparative Study
Europe - epidemiology
Female
Great Britain - epidemiology
Health Policy
Health Services Accessibility - standards
Health Services Research
Humans
Immunization - standards
Infant
Infant mortality
Infant, Newborn
Male
Medical Record Linkage
Population Surveillance
Preventive Health Services - economics - organization & administration - standards
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Social Support
Social Welfare
United States - epidemiology
Wounds and Injuries - etiology - mortality
Abstract
Infant health and survival in the US compare unfavorably with other Western industrial democracies. Circumstances that contribute to favorable pregnancy outcomes in other countries include nearly complete participation of pregnant women in early prenatal care and linkage of care to extensive support benefits. The study reported here extends these earlier observations to preventive health services for children from infancy through adolescence and to the social benefit programs that support their families. This report looks at the condition of children in 10 European countries: Belgium, Denmark, France, the Federal Republic of Germany, Ireland, the Netherlands, Norway, Spain, Switzerland, and the United Kingdom. All of these countries have better infant survival rates than the US, and they all share elements of pluralism in their systems of health care.
Notes
Comment In: Pediatrics. 1992 Dec;90(6):1005-61437418
PubMed ID
1574377 View in PubMed
Less detail

Amoebiasis in a non-endemic country. Epidemiology, presenting symptoms and diagnostic methods.

https://arctichealth.org/en/permalink/ahliterature40267
Source
Scand J Infect Dis. 1983;15(2):207-14
Publication Type
Article
Date
1983
Author
P O Pehrson
Source
Scand J Infect Dis. 1983;15(2):207-14
Date
1983
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Amebiasis - epidemiology
Carrier State - diagnosis - epidemiology
Child
Child, Preschool
Diagnosis, Differential
Diarrhea - diagnosis - etiology
Entamoeba histolytica - isolation & purification
Entamoebiasis - diagnosis - epidemiology
Europe
Feces - parasitology
Female
Humans
Infant
Intestinal Diseases, Parasitic - diagnosis
Liver Abscess, Amebic - diagnosis
Male
Middle Aged
Parasite Egg Count - methods
Retrospective Studies
Sigmoidoscopy
Sweden
Travel
Abstract
392 patients with amoebiasis, diagnosed at Roslagstull Hospital, Stockholm during 10 yr, are reviewed. The disease is increasing in frequency, due both to increased travelling by Swedish citizens and immigration from non-European countries. The risk for an ordinary charter tourist is, however, rather low. Two-thirds of the patients were symptomatic and one-third were regarded as asymptomatic cyst carriers. The importance of repeated examination of stool samples and examinations using different techniques, especially direct microscopy of fresh faeces, is pointed out. The latter technique is in our laboratory shown to be as efficient in cases with no diarrhoea as in those with diarrhoea, with trophozoites demonstrated in the same frequency in both groups. Sigmoidoscopy with scrapings was seldom of diagnostic value.
PubMed ID
6308756 View in PubMed
Less detail

Analysis of Bordetella pertussis populations in European countries with different vaccination policies.

https://arctichealth.org/en/permalink/ahliterature29665
Source
J Clin Microbiol. 2005 Jun;43(6):2837-43
Publication Type
Article
Date
Jun-2005
Author
S C M van Amersfoorth
L M Schouls
H G J van der Heide
A. Advani
H O Hallander
K. Bondeson
C H W von König
M. Riffelmann
C. Vahrenholz
N. Guiso
V. Caro
E. Njamkepo
Q. He
J. Mertsola
F R Mooi
Author Affiliation
Laboratory for Vaccine Preventable Diseases. National Institute of Public Health and the Environment, Anthonie van Leeuwenhoeklaan 9, P.O. Box 1, 3720 BA Bilthoven, The Netherlands.
Source
J Clin Microbiol. 2005 Jun;43(6):2837-43
Date
Jun-2005
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Bacterial Proteins - genetics
Bordetella pertussis - classification - genetics - isolation & purification
Child
Child, Preschool
Europe
Fimbriae Proteins
Health Policy
Humans
Immunization Programs
Infant
Infant, Newborn
Minisatellite Repeats - genetics
Pertussis Vaccine - administration & dosage
Polymorphism, Genetic
Research Support, Non-U.S. Gov't
Serotyping
Vaccination
Virulence Factors - genetics
Whooping Cough - epidemiology - microbiology - prevention & control
Abstract
Despite the widespread use of pertussis vaccines during the last decades, pertussis has remained an endemic disease with frequent epidemic outbreaks. Currently two types of vaccines are used: whole-cell vaccines (WCVs) and recently developed acellular vaccines (ACVs). The long-term aim of our studies is to assess the effect of different vaccination policies on the population structure of Bordetella pertussis and ultimately on the disease burden in Europe. In the present study, a total of 102 B. pertussis isolates from the period 1998 to 2001 from five European countries (Finland, Sweden, Germany, The Netherlands, and France) were characterized. The isolates were analyzed by typing based on variable number of tandem repeats (VNTR); by sequencing of polymorphic genes encoding the surface proteins pertussis toxin S1 and S3 subunits (ptxA and ptxC), pertactin (prn), and tracheal colonization factor (tcfA); and by fimbrial serotyping. The results reveal a relationship between geographic location and VNTR types, the frequency of the ptxC alleles, and serotypes. We have not observed a relationship between the strain characteristics we studied and vaccination programs. Our results provide a baseline which can be used to reveal changes in the B. pertussis population in Europe in the coming years.
PubMed ID
15956406 View in PubMed
Less detail

An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation.

https://arctichealth.org/en/permalink/ahliterature20034
Source
Eur J Haematol. 2001 Jan;66(1):50-6
Publication Type
Article
Date
Jan-2001
Author
M. Remberger
J. Aschan
B. Lönnqvist
S. Carlens
B. Gustafsson
P. Hentschke
S. Klaesson
J. Mattsson
P. Ljungman
O. Ringdén
Author Affiliation
Centre for Allogeneic Stem Cell Transplantation, and Department of Clinical Immunology, Karolinska Institute, Huddinge Hospital, Sweden. Mats.Remberger@impi.ki.se
Source
Eur J Haematol. 2001 Jan;66(1):50-6
Date
Jan-2001
Language
English
Publication Type
Article
Keywords
Acute Disease
Adolescent
Adult
Africa - ethnology
Aged
Anemia, Aplastic - therapy
Asia - ethnology
Child
Child, Preschool
Chronic Disease
Cytomegalovirus - growth & development
Cytomegalovirus Infections - ethnology - etiology
Europe - ethnology
Fanconi Anemia - therapy
Female
Follow-Up Studies
Graft Survival
Graft vs Host Disease - ethnology - etiology - immunology
HLA Antigens - immunology
Hematopoietic Stem Cell Transplantation - adverse effects
Histocompatibility
Humans
Incidence
Infant
Life tables
Logistic Models
Male
Metabolism, Inborn Errors - therapy
Middle Aged
Minor Histocompatibility Antigens - immunology
Multivariate Analysis
Neoplasms - therapy
Nuclear Family
Recurrence
Research Support, Non-U.S. Gov't
Risk factors
Scandinavia - ethnology
Survival Analysis
Sweden - epidemiology
Virus Activation
Abstract
Among 424 HLA identical siblings undergoing stem cell transplantation, 364 were Scandinavians and 60 represented other ethnic groups. The cumulative probabilities of acute graft-versus-host disease grades II-IV were similar in both groups, 17% in Scandinavians and 12% in the others, p = 0.4. In a multivariate analysis, less effective immune suppression with cyclosporine or methotrexate alone (p = 0.001), recipient seropositive for three to four herpes viruses (p = 0.004), CMV-seropositive recipient (p = 0.05) and early engraftment (before day 15) (p = 0.05) were independent risk-factors for acute GVHD grades II-IV. The cumulative probabilities of chronic GVHD were 47% and 68% in the two ethnic populations, respectively (p = 0.004). In multivariate analysis, higher patient age (p
PubMed ID
11168508 View in PubMed
Less detail

[A new method for detecting congenital hearing disorders. Infants are screened by measuring otoacoustic emissions]

https://arctichealth.org/en/permalink/ahliterature33402
Source
Lakartidningen. 1999 Mar 10;96(10):1166-8
Publication Type
Article
Date
Mar-10-1999
Author
L. Hergils
Author Affiliation
ENT Dept, Universitetssjukhuset, Linköping, Sweden.
Source
Lakartidningen. 1999 Mar 10;96(10):1166-8
Date
Mar-10-1999
Language
Swedish
Publication Type
Article
Keywords
Child, Preschool
English Abstract
Europe
Evoked Potentials, Auditory, Brain Stem
Hearing Disorders - congenital - diagnosis - physiopathology
Hearing Tests - statistics & numerical data
Humans
Infant
Infant, Newborn
Mass Screening - statistics & numerical data
Otoacoustic Emissions, Spontaneous
Sweden
United States
Abstract
Despite various infant screening programmes, congenital hearing deficit is normally detected too late. However, the measurement of otoacoustic emissions (OAE) has now proved to be an effective means of assessing neonatal hearing. The article consists in an outline of both international and Swedish experience of universal neonatal screening programmes using OAE testing. Since universal OAE screening was introduced at University Hospital, Linköping, in September 1995, some 6,000 infants have been tested. During the first two years 98.5 per cent of the children participated. Satisfactory bilateral OAE test results were obtained in 97.1 per cent of cases. Where further investigation was necessary, it took the form of auditory brainstem response (ABR) testing during natural rest, or full diagnostic ABR testing under general anaesthesia.
Notes
Comment In: Lakartidningen. 1999 Jun 9;96(23):2835-610405529
PubMed ID
10193119 View in PubMed
Less detail

An international comparison of the estimated effect of the aging of the population on the major cause of disablement, musculoskeletal disorders.

https://arctichealth.org/en/permalink/ahliterature14323
Source
J Rheumatol. 1995 Oct;22(10):1934-40
Publication Type
Article
Date
Oct-1995
Author
E M Badley
M. Crotty
Author Affiliation
Arthritis Community Research and Evaluation Unit, Wellesley Hospital Research Institute, Toronto, Canada.
Source
J Rheumatol. 1995 Oct;22(10):1934-40
Date
Oct-1995
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aging - physiology
Arthritis - epidemiology - physiopathology
Australia - epidemiology
Back Pain - epidemiology - physiopathology
Child
Child, Preschool
Comparative Study
Disabled Persons
Europe - epidemiology
Forecasting
Humans
Infant
Infant, Newborn
Middle Aged
Musculoskeletal Diseases - epidemiology - physiopathology
Prevalence
Research Support, Non-U.S. Gov't
United States - epidemiology
Abstract
OBJECTIVE: To illustrate quantitatively the effect of the aging of the population on the prevalence of chronic disorders by comparing the projected frequency of musculoskeletal (MSK) disorders in 3 comparatively "young" countries, Australia, Canada, and the United States, and 3 comparatively "old" countries, France, the United Kingdom, and Sweden. METHODS: Age specific rates for MSK disability in Canada were applied to World Bank population estimates and projects to estimate prevalence rates and numbers of persons with MSK disability in the years 1985, 2000, 2010, and 2020. RESULTS: The age structure of the populations affected baseline rates for MSK disability. Increases in both prevalence and numbers affected are expected for all countries between 1985 and 2020, up to a 34% increase in prevalence in Canada, and an 88% increase in numbers in Australia. CONCLUSION: The aging of the population is likely to result in a disproportionate increase in the number of people with chronic disabling disorders, which will be taking place against a background of a decreasing or static number of young adults, with implications for meeting needs for health care and community support.
PubMed ID
8991994 View in PubMed
Less detail

An international outbreak of Vero cytotoxin-producing Escherichia coli O157 infection amongst tourists; a challenge for the European infectious disease surveillance network

https://arctichealth.org/en/permalink/ahliterature33056
Source
Epidemiol Infect. 1999 Oct;123(2):217-23
Publication Type
Article
Date
Oct-1999
Author
Pebody, RG
Furtado, C
Rojas, A
McCarthy, N
Nylen, G
Ruutu, P
Leino, T
Chalmers, R
de Jong, B
Donnelly, M
Fisher, I
Gilham, C
Graverson, L
Cheasty, T
Willshaw, G
Navarro, M
Salmon, R
Leinikki, P
Wall, P
Bartlett, C
Author Affiliation
European Programme for Intervention Epidemiology Training, National Public Health Institute, Helsinki, Finland
Source
Epidemiol Infect. 1999 Oct;123(2):217-23
Date
Oct-1999
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Bacterial Toxins - biosynthesis
Case-Control Studies
Child
Child, Preschool
Disease Notification
Disease Outbreaks
Enterotoxins - biosynthesis
Escherichia coli Infections - epidemiology
Escherichia coli O157 - metabolism
Europe - epidemiology
Female
Humans
Infant
Male
Middle Aged
Research Support, Non-U.S. Gov't
Risk factors
Shiga-Like Toxin I
Time Factors
Travel
Water Microbiology
Abstract
In March 1997, an outbreak of Vero cytotoxin-producing Escherichia coli O157 (VTEC) infection occurred amongst holidaymakers returning from Fuerteventura, Canary Islands. For the investigation, a confirmed case was an individual staying in Fuerteventura during March 1997, with either E. coli O157 VTEC isolated in stool, HUS or serological evidence of recent infection; a probable case was an individual with bloody diarrhoea without laboratory confirmation. Local and Europe-wide active case finding was undertaken through national centres, Salm-Net and the European Programme of Intervention Epidemiology, followed by a case-control study. Fourteen confirmed and one probable case were identified from England (7), Finland (5), Wales (1), Sweden (1) and Denmark (1) staying in four hotels. Three of the four hotels were supplied with water from a private well which appeared to be the probable vehicle of transmission. The case-control study showed illness was associated with consumption of raw vegetables (OR 8.4, 95% CI 1-5-48.2) which may have been washed in well water. This investigation shows the importance of international collaboration in the detection and investigation of clusters of enteric infection.
PubMed ID
10579440 View in PubMed
Less detail

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

https://arctichealth.org/en/permalink/ahliterature184937
Source
Arch Dermatol. 2003 Jun;139(6):719-27
Publication Type
Article
Date
Jun-2003
Author
Mark Lebwohl
Enno Christophers
Richard Langley
Jean P Ortonne
Janet Roberts
Christopher E M Griffiths
Author Affiliation
Mount Sinai School of Medicine, New York, NY 10029, USA. lebwohl@aol.com
Source
Arch Dermatol. 2003 Jun;139(6):719-27
Date
Jun-2003
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Canada
Child
Child, Preschool
Chronic Disease
Dose-Response Relationship, Drug
Double-Blind Method
Europe
Female
Humans
Injections, Intramuscular
International Cooperation
Male
Middle Aged
Psoriasis - drug therapy - pathology
Recombinant Fusion Proteins - administration & dosage - adverse effects - therapeutic use
Severity of Illness Index
Treatment Outcome
United States
Abstract
Alefacept, human lymphocyte function-associated antigen 3/immunoglobulin 1 fusion protein, binds to CD2 molecules on the surface of activated T cells, selectively targeting memory-effector (CD45RO+) T cells, which comprise more than 75% of T cells in psoriatic plaques.
To examine the efficacy and tolerability of intramuscular alefacept.
International, randomized, double-blind, placebo-controlled, parallel-group trial.
A total of 507 patients with chronic plaque psoriasis.
Placebo, 10 mg of alefacept, or 15 mg of alefacept administered once weekly for 12 weeks followed by 12 weeks of observation.
Psoriasis Area Severity Index (PASI).
Alefacept treatment was associated with dose-related significant improvements in PASI from baseline. Throughout the study, a greater percentage of patients in the 15-mg group than in the placebo group achieved a significant reduction in PASI. Of patients in the 15-mg group who achieved at least 75% PASI reduction 2 weeks after the last dose, 71% maintained at least 50% improvement in PASI throughout the 12-week follow-up. There were no opportunistic infections and no cases of disease rebound.
Intramuscular administration of alefacept was a well-tolerated and effective therapy for chronic plaque psoriasis and thus represents a convenient alternative to intravenous dosing.
Notes
Comment In: Curr Rheumatol Rep. 2004 Aug;6(4):290-115251079
Comment In: Arch Dermatol. 2004 Feb;140(2):239-4014997878
Comment In: Arch Dermatol. 2003 Jun;139(6):791-312810512
PubMed ID
12810502 View in PubMed
Less detail

Antibody against hepatitis A in seven European countries. I. Comparison of prevalence data in different age groups.

https://arctichealth.org/en/permalink/ahliterature41337
Source
Am J Epidemiol. 1979 Jul;110(1):63-9
Publication Type
Article
Date
Jul-1979
Author
G G Frösner
G. Papaevangelou
R. Bütler
S. Iwarson
A. Lindholm
A. Couroucé-Pauty
H. Haas
F. Deinhardt
Source
Am J Epidemiol. 1979 Jul;110(1):63-9
Date
Jul-1979
Language
English
Geographic Location
Sweden
Norway
Publication Type
Article
Keywords
Adolescent
Adult
Age Factors
Antibodies, viral
Child
Child, Preschool
Comparative Study
Europe
Female
Hepatitis A - epidemiology - immunology
Humans
Infant
Male
Middle Aged
Abstract
Using a solid phase radioimmunoassay, antibody to hepatitis A virus (anti-HAV) was determined in 3890 sera from populations in seven European countries. Prevalence of anti-HAV was lowest in Scandinavian countries and highest in Greece and France. Antibodies were found in 77 (13%) of 602 blood donors in Sweden, in 29 (17%) of 175 blood donors and women taking birth control pills in Norway, in 273 (39%) of 700 blood donors in Switzerland, in 262 (52%) of 505 blood donors in Holland, in 365 (55%) of 661 accident patients in West Germany, in 452 (75%) of 600 blood donors in France and in 530 (82%) of 647 persons in Greece. Prevalence of anti-HAV increased with age in all populations tested, indicating nearly total exposure to HAV in persons over 19 years of age in Greece and in persons over 39 years of age in West Germany, Holland and France. Antibody was found more frequently in rural than in urban populations in Greece and Switzerland. Calculation of the age-specific incidence of HAV infections suggests a remarkable decline in the exposure rate in the last few decades.
PubMed ID
463865 View in PubMed
Less detail

Antibody against hepatitis A in seven European countries. II. Statistical analysis of cross-sectional surveys.

https://arctichealth.org/en/permalink/ahliterature41343
Source
Am J Epidemiol. 1979 Jul;110(1):70-6
Publication Type
Article
Date
Jul-1979
Author
D. Schenzle
K. Dietz
G G Frösner
Source
Am J Epidemiol. 1979 Jul;110(1):70-6
Date
Jul-1979
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Age Factors
Antibodies, viral
Child
Child, Preschool
Cross-Sectional Studies
Europe
Female
Hepatitis A - immunology
Humans
Infant
Male
Mathematics
Middle Aged
Models, Theoretical
Abstract
The age-specific prevalence of hepatitis A antibodies has been analyzed using a catalytic epidemic model for populations in seven European countries: West Germany, Norway, Greece, Switzerland, Holland, France and Sweden. The results indicate a significant decline in the force of infection in recent decades. However, there are substantial differences between the countries, especially between the Scandinavian countries and Greece. The incidence of hepatitis A in Norway and Sweden has declined since 1930, while a downward trend in incidence in Greece may have started only recently.
PubMed ID
313700 View in PubMed
Less detail

255 records – page 2 of 26.